Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once Monthly Darbepoetin Alfa in CKD Dialysis Patients
NCT00096915Phase 3Completed
- Sponsor
- Amgen
- Start
- Oct 2004
- Primary completion
- Nov 2005
- Modality
- Erythropoietins, Colony Stimulating Factors
01
Overview
Phase 3, open-label, single-arm trial of darbepoetin alfa in anemia of chronic kidney disease (CKD-A), sponsored by Amgen. Primary endpoint: Proportion of subjects maintaining mean Hb 11.0-13.0 g/dL at 32 weeks. Started Oct 2004; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT00096915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096915.